title: [Ranibizumab as treatment for myopic choroidal neovascularization].
abstract: OBJECTIVE
  To evaluate the efficacy of intravitreal Ranibizumab as treatment for choroidal neovascularisation due to pathological myopia.
  
  
  METHODS
  A retrospective, non-comparative study of 18 eyes treated with intravitreal injections of Ranibizumab. Ten eyes had been treated previously with photodynamic therapy and eight received Ranibizumab as first therapy. After thorough ophthalmologic examination, fluorescein angiography (FAG) and optical coherence tomography (OCT), intraocular injection of Ranibizumab was performed. In subsequent monthly follow ups and taking into account visual acuity, presence or absence of metamorphopsia, biomicroscopy and OCT examination, further treatment was decided.
  
  
  RESULTS
  Eighteen eyes from 16 patients were finally included. Patients were followed up for a minimum of 6 months. The mean age at initial treatment was 56.4 years. Mean refractive error was -13.3 diopters. Regarding FAG, all neovascular membranes were classical and sub or juxtafoveal localised. At the end of the sixth month after treatment fourteen eyes (77.7%) showed better visual acuity ranging from one or more lines on the Snellen chart, eleven eyes (61.1%) improved two lines or more, three eyes (16.6%) did not show any change and one eye (5.5%) worsened by one line. At 6 months the mean best-corrected visual acuity improved from 0.25 to 0.46 (p= 0.001). The mean central macular thickness decreased from 344.9 to 212.6 (p=0.015).
  
  
  CONCLUSIONS
  Ranibizumab may be a good therapeutic option as treatment for choroidal neovascularisation due to pathological myopia; it improved visual acuity and anatomical features, even in non-responders to photodynamic therapy (Arch Soc Esp Oftalmol 2009; 84: 507-514).
authors.affiliation: Hospital Universitario Miguel Servet, Zaragoza, España. ctorron@salud.aragon.es
authors.forename: C
authors.initials: C
authors.lastname: Torrón
authors.forename: C
authors.initials: C
authors.lastname: Egea
authors.forename: E
authors.initials: E
authors.lastname: Ferrer
authors.forename: O
authors.initials: O
authors.lastname: Ruiz
authors.forename: F M
authors.initials: FM
authors.lastname: Honrubia
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D008268:Macular Degeneration; D008297:Male; D008875:Middle Aged; D009216:Myopia / Q000150:complications; D000069579:Ranibizumab; D012189:Retrospective Studies
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab